Givaudan acquires ingredients portfolio from Amyris 

The acquisition of a major cosmetic ingredients portfolio from Amyris will strengthen Givaudan’s leadership in biotechnology to supply cosmetic ingredients for a sustainable future.

Givaudan, the global leader in Fragrance & Beauty, announced that it has completed the acquisition of a major cosmetic ingredients portfolio from Amyris. Givaudan had announced that it had reached an agreement for this transaction in February 2023. 

Amyris is a leading biotechnology company accelerating the world’s transition to sustainable consumption through its Lab-to-Market™ technology platform in beauty, health and wellness, and flavours and fragrances markets. Amyris and Givaudan have a strong partnership to leverage the value of Amyris’ technology platform for designing, scaling and manufacturing the best performing bio-fermented ingredients. 

Forging forward as a leader in biotech

Maurizio Volpi, President Givaudan Fragrance & Beauty said: “It is an important step for Givaudan as we will reinforce our leadership in biotech, while continuing to offer efficient and sustainable solutions for the beauty industry, thanks to our long-standing partnership with Amyris. The complementary nature of both capabilities will further enhance our ability to support our customers with breakthrough innovations.” 

John Melo, Amyris President and Chief Executive Officer, added: “We are very pleased with the expansion of our long term partnership with Givaudan. Our unique bio-manufactured molecules enable significant expansion to the Givaudan Active Beauty business leadership in the supply of clean, sustainable ingredients. We expect the reach and scale of Givaudan to accelerate our sales growth and to support the beauty industry’s transition to sustainably produced chemistry.”

Committed to a sustainable future

Markus Rassmann, Head of Active Beauty, said: “We are delighted to enrich our market-leading biotech cosmetic ingredients portfolio with the Amyris products. With this acquisition we enhance our unique biotech palette, leading the market towards a more sustainable future.” 

While terms of the deal have not been disclosed, Amyris’ cosmetic business would have represented approximately $30 million of incremental sales to Givaudan’s results in 2022 on a proforma basis. Givaudan funded the transaction from existing resources.